Treos Bio updates results of phase 1/2 trial of its cancer vaccine
Category: #health  By Pankaj Singh  Date: 2019-09-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Treos Bio updates results of phase 1/2 trial of its cancer vaccine

Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient).

Treos Bio Ltd. has reportedly updated positive outcomes on the second segment of phase 1/2 trial (OBERTO) along with PolyPEPI1018 cancer injection. The second part of the trial is a supplement to the company’s maintenance treatment in patients suffering from microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Apparently, the phase 1/2 study is a single-arm, open-label, multicenter trial. The trial aims to evaluate the tolerability, safety, preliminary efficacy, and immunogenicity of single dose or multiple doses of PolyPEPI1018. The doses are intended as a supplement to maintenance treatment in subjects suffering from metastatic colorectal cancer following the first-line induction chemotherapy. Initial outcomes from the first part of the trial were exhibited at ASCO 2019 and outcomes of the second part have been made available now.

Reportedly, patients with mCRC in first line setting were given up to three dosages of PolyPEPI1018 vaccine (0.2 mg/peptide) 12 weeks apart. Doses were given following the transition to maintenance treatment with bevacizumab and fluoropyrimidine. Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient). Later, these responses were calculated after one series of vaccination.

Joleen M. Hubbard, M.D., principal investigator of the OBERTO study, Mayo Clinic, reportedly stated that in addition to the unforeseen tumor responses examined for a few of the patients, it has been very reassuring that most of the subjects on multiple doses controlled their disorder till the completion of the follow-up time and beyond. The investigators have planned to continue registration of more patients in the trial and follow them for an even extended interval this time, she further added.

Reports confirm that in addition to the presentation of poster of the OBERTO study outcomes, three more posters will be displayed by Treos Bio at ESMO 2019. Those extra posters will be associated with its PEPI based platform technology and science.

Source credits:

https://finance.yahoo.com/news/treos-bio-reports-updated-positive-091500643.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...

Celltrion receives positive opinion for Remsima® SC from CHMP
Celltrion receives positive opinion for Remsima® SC from CHMP
By Pankaj Singh

Celltrion Healthcare, one of the leading biopharmaceutical companies headquartered in Incheon, South Korea, has reportedly announced that CHMP (the Committee Medicinal Products for Human Use) has recommended the compan...